title: Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
authors.affiliation: Department of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA. george_segel@urmc.rochester.edu
authors.forename: George B
authors.initials: GB
authors.lastname: Segel
authors.forename: William
authors.initials: W
authors.lastname: Simon
authors.forename: Marshall A
authors.initials: MA
authors.lastname: Lichtman
mesh_terms: D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000473:pathology* / Q000628:therapy; D000986:Antisickling Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D004906:Erythrocyte Count; D004913:Erythrocytes, Abnormal / Q000473:pathology*; D005319:Fetal Hemoglobin / Q000032:analysis*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007223:Infant; D055815:Young Adult
chemical_list: D000986:Antisickling Agents; D005319:Fetal Hemoglobin; D006918:Hydroxyurea